This event has also been shown in tamoxifen-treated breast cancer samples, where the PAX2-positive AIB-1-negative tumors have the best prognosis and the lowest percentage of ERBB2-positive cells (Hurtado et al. 2008). Here, PAX2 is linked to breast carcinoma.